- Home
- MYGN vs MSIF Comparison
MYGN vs MSIF Comparison
Compare MYGN & MSIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MSIF
- Stock Information
- Founded
- MYGN 1991
- MSIF 2011
- Country
- MYGN United States
- MSIF United States
- Employees
- MYGN N/A
- MSIF N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MSIF
- Sector
- MYGN Health Care
- MSIF
- Exchange
- MYGN Nasdaq
- MSIF NYSE
- Market Cap
- MYGN 744.7M
- MSIF 795.9M
- IPO Year
- MYGN 1995
- MSIF N/A
- Fundamental
- Price
- MYGN $5.34
- MSIF $16.20
- Analyst Decision
- MYGN Hold
- MSIF Buy
- Analyst Count
- MYGN 15
- MSIF 5
- Target Price
- MYGN $15.14
- MSIF $18.50
- AVG Volume (30 Days)
- MYGN 1.3M
- MSIF 85.1K
- Earning Date
- MYGN 08-05-2025
- MSIF 05-12-2025
- Dividend Yield
- MYGN N/A
- MSIF 8.90%
- EPS Growth
- MYGN N/A
- MSIF N/A
- EPS
- MYGN N/A
- MSIF 1.50
- Revenue
- MYGN $831,300,000.00
- MSIF $134,105,000.00
- Revenue This Year
- MYGN N/A
- MSIF $9.98
- Revenue Next Year
- MYGN $6.68
- MSIF $10.94
- P/E Ratio
- MYGN N/A
- MSIF $10.89
- Revenue Growth
- MYGN 7.38
- MSIF N/A
- 52 Week Low
- MYGN $3.81
- MSIF $14.01
- 52 Week High
- MYGN $29.30
- MSIF $18.10
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- MSIF N/A
- Support Level
- MYGN $4.90
- MSIF N/A
- Resistance Level
- MYGN $5.83
- MSIF N/A
- Average True Range (ATR)
- MYGN 0.28
- MSIF 0.00
- MACD
- MYGN 0.04
- MSIF 0.00
- Stochastic Oscillator
- MYGN 54.21
- MSIF 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MSIF MSC INCOME FUND INC
MSC Income Fund Inc is a non-diversified closed-end management investment company. The investment objective is to generate current income through debt and equity investments and the secondary objective is to generate long-term capital appreciation through such investments. The company invests in senior secured term loans, second lien loans, and mezzanine debt and selected equity investments issued by lower middle-market and middle-market companies.